MKNK1 and prostate cancer: We propose that AR/AR-V7 and Mnk1/2 degraders could be effective in prostate cancer patients with upregulation of AR/AR-V7 and Mnk1/2 proteins, which currently represents a pressing therapeutic challenge [19,20,28,29,30,31].